The proposed legislation, General Assembly Raised Bill No. 5482, aims to mandate that both private and Medicaid health insurance plans provide coverage for a twelve-month supply of prescription hormone therapy and contraceptive drugs, devices, or products. Effective January 1, 2027, the bill defines "prescription hormone therapy" as FDA-approved drugs used to manage hormone levels, excluding certain medications like glucagon-like peptide-1. Health insurance policies must reimburse for a full year's supply of these therapies, unless the insured or prescribing provider requests a smaller amount, or if the therapy is classified as a controlled substance, in which case reimbursement will be limited to the maximum refills allowed by law.

Additionally, the bill stipulates that the Commissioner of Social Services must ensure Medicaid coverage for a twelve-month supply of medically necessary prescription hormone therapy and contraceptives, with similar conditions for dispensing as outlined for private insurance. The legislation emphasizes the importance of providing comprehensive access to these essential health services, thereby promoting better health outcomes for individuals requiring hormone therapy and contraception.